Orion Biotechnology to Present OB-002 in Vitro Potency Data at the 10th International AIDS Society HIV Science Meeting in Mexico City in July 2019

OTTAWA, Ontario, March 28, 2019 /PRNewswire/ — Orion Biotechnology Canada Ltd., today announced that it will be presenting data on the potency of OB-002, their CCR5 antagonist currently in development for HIV prevention and oncology indications, at the 10th IAS HIV Science Meeting that will be held in Mexico City in July 2019.

Continue Reading